| ABMT Stock | | | USD 0.0006 0.00 0.00% |
CEO
Ms. Wang Hui is Chief Executive Officer and Director of the Company. Ms. Wang started her career at Hainan Xinte Pharmaceutical Ltd in China in 1990. Ms. Wang worked her way up from cashier to sales representative and then to sales manager. She then worked as District Manager of Southern China with Hainan Tianfeng Pharmaceutical Ltd, from 1995 to 2000 and as General Manager with Hainan Yichen Pharmaceutical Ltd. from 2001 to 2004. She is now the General Manager of Shenzhen Changhua. Ms. Wang has skills and experience in RA, marketing and business development in Chinese medical industry. The Board concluded that Hui Wang should serve as a Director due to her skills and experience in pharmaceutical sales and business development. since 2009.
| Age | 53 |
| Tenure | 16 years |
| Phone | 718 766 7898 |
| Web | https://abtlafleur.com |
Advanced Biomedical Management Efficiency
The company has return on total asset
(ROA) of
(0.7811) % which means that it has lost $0.7811 on every $100 spent on assets. This is way below average. Advanced Biomedical's management efficiency ratios could be used to measure how well Advanced Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.
Advanced Biomedical Technologies currently holds 6.36
M in liabilities. Advanced Biomedical has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Advanced Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Advanced Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Advanced Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Advanced to invest in growth at high rates of return. When we think about Advanced Biomedical's use of debt, we should always consider it together with cash and equity.
Similar Executives
Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York. Advanced Biomedical operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 17 people. Advanced Biomedical Technologies [ABMT] is a
Pink Sheet which is traded between brokers over the counter.
Management Performance
Advanced Biomedical Leadership Team
Elected by the shareholders, the Advanced Biomedical's board of directors comprises two types of representatives: Advanced Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Advanced. The board's role is to monitor Advanced Biomedical's management team and ensure that shareholders' interests are well served. Advanced Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Advanced Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Lynch, Chief Technologies | |
| Hui Wang, CEO, Controller, Director and Member of Disclosure Committee | |
| Chi Yu, President, Treasurer, Compliance Officer, Director and Member of Disclosure Committee | |
| Kai Gui, CFO, Secretary, Director and Member of Disclosure Committee | |
| Pr MD, Chairman China | |
Advanced Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Advanced Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Advanced Pink Sheet Analysis
When running Advanced Biomedical's price analysis, check to
measure Advanced Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Advanced Biomedical is operating at the current time. Most of Advanced Biomedical's value examination focuses on studying past and present price action to
predict the probability of Advanced Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Advanced Biomedical's price. Additionally, you may evaluate how the addition of Advanced Biomedical to your portfolios can decrease your overall portfolio volatility.